FinBERT, a financial-language model, scores this headline as positive (91% confidence). That is the news tone only — not the full stock rating.
Stocks › VRTX
Vertex Pharmaceuticals Inc / Ma (VRTX) stock analysis
WEAK BUY 18% confidence · analysed Nov 2, 2026
On Nov 2, 2026, our model rated Vertex Pharmaceuticals Inc / Ma (VRTX) WEAK BUY with 18% confidence at a price of $553.15. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$553.15
Technical picture
The 14-day RSI is 76, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is 2.0x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $507.92 and the swing low is $412.27; traders often treat these as resistance and support.
Fundamentals
In its latest quarter it earned $4.73 per share, which missed the $4.75 analysts expected, with revenue +12.5% year over year.
Trade plan from the model
The model's long / bullish plan uses an entry near $553.15, a target of $576.56 (+4.2%) and a stop-loss at $519.15 (-6.1%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 12, 2026 whatever the price does.
Entry$553.15
Target$576.56
Stop-loss$519.15
Reassess byNov 12, 2026
The model's one-paragraph read
Leans BUY — composite score +0.18 (WEAK BUY). Technicals: RSI 75.58, MACD bullish, price above SMA50. Financial results: YoY revenue +12.5%, last EPS surprise -0.4%. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: positive. Suggested levels: entry $553.15, target $576.56, stop-loss $519.15, exit by 2026-11-12 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for VRTX
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 2, 2026 | WEAK BUY | 18% | $553.15 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on VRTX
Nov 2, 2026 · Vertex Continues Its Buy-Zone Run After Hiking 2026 Sales Guidance
- Nov 2, 2026: Vertex Continues Its Buy-Zone Run After Hiking 2026 Sales Guidance (Investor's Business Daily)
Frequently asked questions
Is VRTX a buy right now?
As of Nov 2, 2026, our automated model rates Vertex Pharmaceuticals Inc / Ma (VRTX) WEAK BUY with 18% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for VRTX?
The model's most recent plan targets $576.56 with a stop-loss at $519.15, from an entry near $553.15.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.